Form 4: Director Jean-Jacques Bienaime Reports IMNM Transactions

Director Jean-Jacques Bienaime disclosed a series of short-swing common stock transactions in Immunome, Inc. on June 5, 2026.

Summary

• Director Jean-Jacques Bienaime executed multiple buy and sell transactions of Immunome, Inc. (IMNM) common stock on June 5, 2026.
• The transactions involved the sale of 10,500 shares and the purchase of 10,500 shares, resulting in a net change of zero in total holdings.
• The reporting person identified a short-swing profit of $155 resulting from these transactions.
• The reporting person has agreed to disgorge the $155 profit to the company in compliance with Section 16(b) of the Securities Exchange Act.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral event; while the trading activity itself is benign, the technical violation of Section 16(b) reflects poorly on the director's administrative compliance.

Positives

• The director maintains a consistent ownership position in the company following the transactions.
• The reporting person proactively identified and disclosed the short-swing profit, demonstrating transparency and regulatory compliance.

Negatives

• The occurrence of a short-swing profit transaction indicates a lack of coordination or oversight regarding Section 16(b) trading restrictions.
• The need to disgorge profits to the issuer highlights an administrative error in trading activity.

Risks

• Potential for regulatory scrutiny regarding compliance with Section 16(b) short-swing profit rules.
• Reputational risk associated with insider trading compliance errors.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person acknowledged that the sales were matchable under Section 16(b) and agreed to pay the realized profit to the issuer.

Industry Context

StockSavvy.ai notes that while insider trading disclosures are routine, short-swing profit violations are relatively uncommon for experienced directors and typically reflect administrative oversight rather than strategic shifts.

Comparison to Industry Standards

• Compliance with Section 16(b) is a standard regulatory requirement for all public company directors.
• The voluntary disclosure and agreement to disgorge profits align with standard corporate governance practices for correcting inadvertent trading violations.

Stakeholder Impact

• Minimal impact on shareholders as the net share position remains unchanged and the profit is returned to the company.

Next Steps

• Disgorgement of $155 in profits to Immunome, Inc.

Key Dates

Keywords

Immunome, IMNM, Insider Trading, Form 4, Section 16, Director Transactions